Skip to main content

Discover more about ENTRESTO® 

Find educational resources to learn more about heart failure (HF) and view educational content from your peers.

All physicians were compensated by Novartis Pharmaceuticals Corporation to conduct their presentation.

The Cardiac Stage: Spotlighting A HFrEF Patient Journey

This video features Dr Munir Janmohamed, an advanced heart failure cardiologist, discussing his clinical experience and perspective in diagnosing and treating patients with HFrEF. He shares the importance of the cardiologist's role and how he supports his patients throughout their HF journey.

 

Clinical Data in HFmrEF and HFpEF: An Introduction to PARAGLIDE-HF

This video features an overview of ENTRESTO clinical data in patients with HFmrEF and HFpEF, including data from the PARAGLIDE-HF clinical trial (median LVEF 55%).

 

Listen to your peers discuss heart failure

All physicians were compensated by Novartis Pharmaceuticals Corporation to conduct their presentation.

Conversations With Cardiologists: A Paradigm Shift, It's Time to Switch

This podcast features a discussion between two cardiologists, Javed Butler, MD, MBA, MPH, and Stephanie Saucier, MD, FACC, RVPI, and is hosted by primary care physician Jennifer Caudle, DO. Dr Butler and Dr Saucier discuss when to consider switching heart failure therapies in patients with reduced ejection fraction by reviewing the 2022 AHA/ACC/HFSA HF Guideline and the clinical data for ENTRESTO from PARADIGM-HF.

Conversations With Cardiologists: Clinical Perspectives on the Treatment of HFmrEF and HFpEF

This podcast is hosted by primary care physician Jennifer Caudle, DO, and features two cardiologists, Sophia Airhart, MD, the Medical Director of the Heart Failure, Mechanical Circulatory Support and Pulmonary Hypertension program at Saint Alphonsus Medical Center in Boise, Idaho, and Jayne Morgan, MD, Executive Director of Health and Community Education at Piedmont Healthcare in Atlanta, Georgia, discussing the current and historical clinical guidance on the treatment of HFmrEF and HFpEF, as well as the clinical data for ENTRESTO from PARAGLIDE-HF.

Download helpful resources below

HCP Dosing Flashcard

HCP Dosing Flashcard

This informational handout on available dosing options is designed to help you prescribe ENTRESTO with confidence.
Download
Entresto Initiation Guide

ENTRESTO Initiation Guide for Providers

All-in-one guide to aid HCPs in replacing ACEi/ARB with ENTRESTO for appropriate patients with heart failure.
Download
Clinical Trial Booklet

Clinical Trial Booklet

A summary of each clinical trial, including the aim of each trial, the population tested, and the study drugs involved.
Download
PARAGLIDE Core Brochure

PARAGLIDE-HF Core Brochure

A comprehensive resource that summarizes PARAGLIDE-HF and shows HCPs why ENTRESTO should be an essential part of heart failure treatment.
Download
ACC ECDP Flashcard

ACC ECDP Flashcard

A helpful recap of the 2024 ACC Expert Consensus Decision Pathway for the treatment of HFrEF and the latest recommendations therein.
Download
2022 AHA/ACC/HFSA HF Guideline Pocket Guide

2022 AHA/ACC/HFSA HF Guideline Pocket Guide

Quick access to select recommendations for the pharmacological management of Stages C and D in heart failure.
Download
Outpatient Digital Slim Jim

Outpatient Digital Slim Jim

Individual pieces designed to make HCPs rethink how they treat heart failure and why ENTRESTO can help.
Download
You’ve Got Questions, We’ve Got Answers

You've Got Questions, We've Got Answers

A simple tool to show HCPs why they should consider ENTRESTO, who they should consider it for, and how to best do so.
Download

Contact a Sales Specialist

If you're looking for more information about ENTRESTO, connect with one of our Sales Specialists. 

  • Clinical product information 

  • General access information 

  • Co-pay and adherence support options  

  • Sales Specialists do not have access to patient-level data 

Discover support and resources to help your patients start on ENTRESTO

View ENTRESTO clinical and biomarker data for HFrEF

Learn how ENTRESTO impacted hospitalization in HFpEF patients with LVEF below normal* vs valsartan

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Definitions
ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin ‖ receptor blocker; ECDP, Expert Consensus Decision Pathway; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LAE, left atrial enlargement; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy.

Reference
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.